TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.
1 report, 1 independent
Updated Aug 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
-
Wedbush Securities
US financial services and investment firm
Nothing else this week.
Related events
- TD Cowen reiterated a buy rating on MBX Biosciences shares, and Citigroup restated an outperform rating on the company.
- Bio-Techne shares traded on Nasdaq, and TD Cowen reiterated a Buy rating with a $65 price target.
- Analyst rating updates for Krystal Biotech, including a buy rating from TD Cowen and a consensus rating from MarketBeat.
- TD Cowen restated a 'buy' rating on Affiliated Managers Group (AMG) on June 6, 2026.
- MarketBeat reported that TD Cowen increased its price objective and gave a buy rating for an unnamed company.